Genetic Technologies Stock Forecast, Price & News

Wall Street analysts have given Genetic Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Genetic Technologies saw a increase in short interest in the month of July. As of July 30th, there was short interest totaling 1,060,000 shares, an increase of 27.6% from the July 15th total of 830,800 shares. Based on an average daily trading volume, of 658,100 shares, the days-to-cover ratio is presently 1.6 days.
View Genetic Technologies' Short Interest.

Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GENE shares have increased by 40.7% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Genetic Technologies include CASI Pharmaceuticals (CASI), Humacyte (HUMA), Genfit (GNFT), aTyr Pharma (LIFE), Tscan Therapeutics (TCRX), Ayala Pharmaceuticals (AYLA), ADMA Biologics (ADMA), Evaxion Biotech A/S (EVAX), Miromatrix Medical (MIRO), ERYTECH Pharma (ERYP), IN8bio (INAB), LogicBio Therapeutics (LOGC), Big Cypress Acquisition (BCYP), Dyadic International (DYAI) and Freeline Therapeutics (FRLN).
View all of GENE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX).

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Genetic Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Simplex Trading LLC (0.00%), Morgan Stanley (0.40%), Morgan Stanley (0.40%), Group One Trading L.P. (0.00%) and Susquehanna Fundamental Investments LLC (0.24%).

GENE stock was sold by a variety of institutional investors in the last quarter, including Susquehanna Fundamental Investments LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., and Cutler Group LP.

GENE stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC, Morgan Stanley, Morgan Stanley, Group One Trading L.P., Susquehanna International Group LLP, and Jump Financial LLC.

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GENE stock can currently be purchased for approximately $3.32.

Genetic Technologies has a market capitalization of $51.05 million and generates $90,000.00 in revenue each year.

Genetic Technologies was founded in 1989.

The official website for Genetic Technologies is www.gtgcorporate.com.

Genetic Technologies is headquartered at 60-66 HANOVER STREET, FITZROY C3, 3065.

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at (138) 412-7000 or via email at [email protected]